Novel insights into the hepatoprotective mechanisms of SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

The sodium-glucose cotransporter (SGLT)2 inhibitor empagliflozin (EMPA) is a hypoglycemic drug for patients with type 2 diabetes mellitus and cardiovascular disease. The mechanisms underlying the beneficial effects of EMPA in counteracting Metabolic Associated Fatty Liver Disease (MAFLD) are poorly...

Descrición completa

Detalles Bibliográficos

Principais autores:	F. Comella, A. Aragón-Herrera, S. Melini, N. Opallo, S. Feijóo-Bandín, N. P. Navatti, G. Mattace Raso, O. Gualillo, C. Pirozzi, F. Lago-Paz, R. Meli
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-09-01
Series:	Frontiers in Pharmacology
Assuntos:	metabolic-associated fatty liver disease (MAFLD) ZDF rat glucose and lipidmetabolism insulin sensitivity hepatic inflammation macrophage polarization
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1649630/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!